Email this article to a friend
Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial
Arthritis Research & Therapy 2012, 14:R6 doi:10.1186/ar3554
